➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Johnson and Johnson
Express Scripts
AstraZeneca
Harvard Business School

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CAPMATINIB HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Capmatinib Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02750215 A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor Recruiting Novartis Phase 2 2016-05-01 This research study is studying capmatinib as a treatment for advanced non-small cell lung cancer with MET exon 14 skipping, where the participant has already received prior therapy with a MET inhibitor.
NCT02750215 A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor Recruiting Massachusetts General Hospital Phase 2 2016-05-01 This research study is studying capmatinib as a treatment for advanced non-small cell lung cancer with MET exon 14 skipping, where the participant has already received prior therapy with a MET inhibitor.
NCT03040973 Roll-over Study for Patients With cMET-dependent Malignancies Who Previously Completed a Novartis Capmatinib Study Not yet recruiting Novartis Pharmaceuticals Phase 4 2017-05-31 The rollover study will provide continued treatment and assessment of long-term safety follow-up in patients receiving capmatinib (INC280) in a Novartis sponsored study and in the opinion of the Investigator would benefit from continued treatment.
NCT03240393 Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) Not yet recruiting Novartis Pharmaceuticals Phase 2 2017-11-30 A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult Chinese patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease as measured by overall response rate (ORR). The study will also evaluate safety and pharmacokinetics of INC280.
NCT03484923 Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma Recruiting Novartis Pharmaceuticals Phase 2 2018-09-11 The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma
NCT03647488 Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer Recruiting Novartis Pharmaceuticals Phase 2 2018-12-26 This is a clinical research study and the purpose of the study is to learn whether the combination of the drugs capmatinib plus spartalizumab helps to control lung cancer better compared to a single agent chemotherapy (docetaxel) and whether it is safe when given to patients with NSCLC. Capmatinib is an oral drug that is called a "targeted" medicine: this means it targets particular processes, which may not be working properly in the cancer cells in your body (called dysregulation) and which may be causing your disease. Spartalizumab is an antibody (a kind of protein that binds to a specific "target" protein). By blocking its "target" protein, called PD-1, spartalizumab may increase the activity of a certain type of cells in your immune system, which may reduce the growth of your tumor. Docetaxel is a standard chemotherapy medicine commonly used to treat your type of lung cancer. This standard, anti-cancer medicine is a cytotoxic chemotherapy that is being compared with capmatinib and spartalizumab. The reason for this study is to find out which of these two treatments (combination of capmatinib plus spartalizumab OR docetaxel alone) helps to control lung cancer better.
NCT03742349 Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). Not yet recruiting Novartis Pharmaceuticals Phase 1 2018-12-21 This is a Phase Ib, open label, dose escalation study of spartalizumab + LAG525 in combination with NIR178, capmatinib, MCS110, or canakinumab, followed by a dose expansion in adult patients with advanced or metastatic TNBC. During the dose-escalation part of each treatment arm, patients will be treated with fixed doses of spartalizumab + LAG525 in combination with partner investigational drugs to be escalated until the MTD is reached or a lower RDE is established: NIR178, capmatinib, MCS110, or canakinumab. It is anticipated that other partner study drugs may be added in the future by protocol amendment. After the determination of the MTD/RDE for a particular treatment arm, dose expansion may begin in that arm in order to further assess safety, tolerability, PK/PD, and anti-tumor activity of each combination at the MTD/RDE. Dose expansion arms may initiate only after consideration by the Investigators and Novartis of all available toxicity information, the assessment of risk to future patients from the BLRM, and the available PK, preliminary efficacy, and PD information. There is no requirement for dose-escalation treatment arms reaching an MTD/RDE to proceed to dose expansion.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Capmatinib Hydrochloride

Condition Name

Condition Name for Capmatinib Hydrochloride
Intervention Trials
Carcinoma, Non-Small-Cell Lung 3
Malignant Non-small Cell Neoplasm of Lung Stage IV 1
Triple Negative Breast Cancer (TNBC) 1
Soft Tissue Sarcoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Capmatinib Hydrochloride
Intervention Trials
Carcinoma, Non-Small-Cell Lung 6
Lung Neoplasms 5
Carcinoma 2
Triple Negative Breast Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Capmatinib Hydrochloride

Trials by Country

Trials by Country for Capmatinib Hydrochloride
Location Trials
United States 4
Spain 2
France 2
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Capmatinib Hydrochloride
Location Trials
Arkansas 1
California 1
Michigan 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Capmatinib Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Capmatinib Hydrochloride
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 2 7
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Capmatinib Hydrochloride
Clinical Trial Phase Trials
Not yet recruiting 8
Recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Capmatinib Hydrochloride

Sponsor Name

Sponsor Name for Capmatinib Hydrochloride
Sponsor Trials
Novartis Pharmaceuticals 9
Institut Bergonié 1
Commissariat A L'energie Atomique 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Capmatinib Hydrochloride
Sponsor Trials
Industry 10
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Express Scripts
Johnson and Johnson
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.